Latest Biologic Stories

Anti-CD20-Interferon Alpha Fusion Protein (IGN002) is a promising drug candidate for NHL patients who are resistant to standard therapy WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6( )million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change...

Express Scripts' Three-Year Drug Trend Forecast Projects That Three of the Four Costliest Therapy Classes Will Be Specialty Conditions ST. LOUIS, May 21, 2013 /PRNewswire/ -- U.S. spending on specialty prescription drugs -- those used to treat chronic, complex diseases such as cancer, multiple sclerosis and rheumatoid arthritis -- is projected to increase 67 percent by the end of 2015, according to a forecast released today by Express Scripts (NASDAQ: ESRX). (Logo:...

HASSELT, Belgium, May 21, 2013 /PRNewswire/ -- Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies(TM), a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation are listed below. Dr Vaeck will highlight Complix' recent progress in applying its...

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 2(nd) Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at 10:00 a.m. (Eastern Time). A live webcast of Synthetic Biologics' presentation can be...

LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer. "RYI-008, with its unprecedented femtamolar potency and amazing long...

SEATTLE, COPENHAGEN, Denmark and SHANGHAI, May 14, 2013 /PRNewswire/ -- CMC Biologics today announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics' proprietary CHEF1® high-productivity expression plasmid will be utilized for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame. Specific terms of the agreement were not disclosed....

Thomson Reuters report offers sneak peek into future of U.S. biosimilar market PHILADELPHIA, May 14, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, "An Outlook on U.S. Biosimilar Competition," providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market and key...

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Oncobiologics, Inc. announced today that Zhejiang Huahai Pharmaceutical Co., Ltd and Oncobiologics have signed an alliance agreement for the development, manufacture and commercialization of biosimilar monoclonal antibody products. The scope of the agreement includes exclusive commercialization by Huahai of four biosimilars developed by Oncobiologics and manufactured in China at a Huahai biologics facility for the China market, and will...

CHICAGO, May 3, 2013 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging and high tech pharmacy automation, today announced a co-marketing agreement with Biologics Modular. Biologics Modular designs and manufacturers modular facilities that serve as self-contained biorepositories, biomanufacturing suites and research suites. "As we look to accelerate PosiRx®...

BEIJING, May 2, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2013 financial results on Wednesday, May 8, 2013 after the market closes. The Company's management will hold a conference call at 7:30 a.m. ET on Thursday, May 9, 2013 to discuss first quarter 2013 results. Listeners...